Newsroom

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the achievement of a clinical milestone under its license agreement with TG Therapeutics, Inc. (Nasdaq: TGTX). The milestone payment for azercabtagene zapreleucel (azer-cel) was triggered by progress of a Phase 1 clinical trial of azer-cel in progres...

ATLANTA--(BUSINESS WIRE)--KNAPP North America, the reliable technology partner for value chain innovation, will present its latest advancements in warehouse robotics at MODEX 2026 in Atlanta, April 13–16, at Booth B13119 in Hall B. Customer demands such as same- and next-day delivery are pushing logistics systems harder than ever, increasing the need for efficiency, resilience and sustainable growth. At the same time, automation and AI are creating opportunities that were unimaginable just a fe...

PORTSMOUTH, N.H.--(BUSINESS WIRE)--The Board of Directors of Albany International Corp. (NYSE: AIN) today declared a quarterly dividend of $0.28 per share on the Company’s Class A Common Stock. The dividend is payable April 7, 2026, to shareholders of record on March 20, 2026. About Albany International Corp. Albany is a leading materials science developer and manufacturer of engineered components, using advanced materials processing and automation capabilities, with two core businesses: Machin...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis to acquire animal genomics business from Neogen, strengthening the company's leadership in Precision Animal Health...

LANSING, Mich.--(BUSINESS WIRE)--Neogen Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today it has entered into a definitive agreement to sell its global genomics business to Zoetis Inc. (“Zoetis”), the world’s leading animal health company, for $160 million, subject to customary closing adjustments. The planned divestiture, which had been previously announced, was part of the company’s portfolio review strategy to simplify the business and focus on core s...

WILLOW PARK, Texas--(BUSINESS WIRE)--ProFrac Holding Corp. (NASDAQ: ACDC) ("ProFrac" or the "Company") announced today that it will report its fourth quarter and full year 2025 financial results prior to the Company's conference call, which will be webcasted on Thursday, March 12, 2026, at 11:00 a.m. Eastern / 10:00 a.m. Central. To register for and access the event, please click here. An archive of the webcast will be available shortly after the call’s conclusion on the IR Calendar section of...

BOSTON--(BUSINESS WIRE)--DraftKings Inc. (Nasdaq: DKNG) (“DraftKings” or the “Company”) today outlined an expanded growth strategy and long-term financial framework, including its participation in what management expects to be a $55 billion to $80 billion 2030 industry gross revenue opportunity. The Company is also increasing deployment of AI across the platform to drive efficiency and operating leverage. Additional details will be provided at DraftKings’ 2026 Virtual Investor Day, which will b...

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its sebetralstat clinical trial program presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and the Western Society of Allergy, Asthma & Immunology (WSAAI) 63rd Annual Scientific Session. The presentations demonstrate a significant shift in how patients manage hereditary angioedema (HAE) attacks when provided with...

NEW YORK--(BUSINESS WIRE)--ReBound & Reflex Sales Group Announce Partnership to Maximize the Value and Lifecycle of Surplus Shopper Returns...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provides financial guidance for full year 2026. "Thanks to the entire Xeris organization, 2025 was a transformational year, marked by focused execution, record reven...